一种细菌毒素作为一种新型抗癌药物,调节瘤微环境
Lingyu Li1, Pauline Evain1, Michael Timothy Phillips1
1Department of Molecular Biology, Umeå Centre for Microbial Research (UCMR), Umeå University, SE-90187, Umeå, Sweden.
Cell death & disease
|December 1, 2025
概括
马卡是一种Vibrio cholerae细胞毒素,作为结肠直肠癌 (CRC) 治疗方法具有前景. 它有效地降低了瘤生长,并增强了瘤微环境 (TME) 中的免疫细胞活性,没有系统性毒性.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 微生物学 微生物学
背景情况:
- 结肠直肠癌 (CRC) 是全球癌症相关死亡的主要原因.
- 目前的CRC治疗具有显著的副作用,需要新的治疗方法.
- 瘤微环境 (TME) 在CRC进展和免疫逃避中发挥着关键作用.
研究的目的:
- 评估MakA的抗癌性质,这是来自Vibrio cholerae的细胞毒素.
- 在CRC小鼠模型中研究MakA对TME和免疫细胞透的影响.
- 评估MakA对结直肠癌的安全性和治疗潜力.
主要方法:
- 在大肠直肠癌的小鼠模型中,对MakA进行全身治疗.
- 在TME中分析瘤生长,癌细胞亡和免疫细胞透.
- 评估白细胞招募,激活和产生促炎媒介的情况.
主要成果:
- 发现MakA的使用是无毒的,并没有诱导全身组织损伤.
- 马卡显著抑制瘤生长,并促进癌细胞亡.
- 在TME中,MakA增加了免疫细胞的丰富性,包括中性粒细胞和巨细胞,增强了抗新生菌免疫反应.
结论:
- 通过调节TME免疫反应,MakA显示出显著的抗癌特性.
- 马卡增强白细胞的招募和激活,有助于抗瘤效应.
- 马卡代表了一种潜在的新,不那么有害的结直肠癌治疗策略.
相关概念视频
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Tumor Immunotherapy
1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
The Tumor Microenvironment
7.6K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
7.6K
Drugs that Destabilize Microtubules
3.6K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
3.6K
Drugs that Stabilize Microtubules
2.6K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.6K
Mitogens and the Cell Cycle
7.7K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.7K


